Medtronic (NYSE: MDT) saw its shares jump 3.2% in early trading on Tuesday, reaching $93.56, following the release of its fiscal first-quarter results and a strategic investment announcement. The medical device maker reported revenue of $9.756 billion for the quarter ended July 31, 2026, a 13.7% increase year-over-year, and adjusted earnings per share of $1.45, both beating analyst expectations.
The company also raised its full-year guidance, projecting organic sales growth of 7.25% to 7.75% for fiscal 2027, up from its previous forecast of 6.75% to 7.25%. Adjusted earnings per share guidance was lifted to a range of $5.94 to $6.00, with the floor raised by four cents. This optimistic outlook reflects confidence in the company's growth trajectory and operational performance.
In a significant strategic move, Medtronic announced an approximately $700 million investment in Cornerstone Robotics, a stake that represents 37.6% of its first-quarter adjusted net profit. The partnership grants Medtronic distribution rights for Cornerstone's Sentire surgical system in markets outside the United States, complementing its own Hugo robotic-assisted surgery platform. The company plans to offer both systems to address a broader range of surgical needs.
Geoff Martha, Chief Executive Officer of Medtronic, highlighted the "broad-based strength of performance across our businesses," noting that all four of the company's primary business segments delivered robust growth. Cardiovascular led the way with an 18.9% increase in organic sales, followed by Diabetes at 14.9%, Medical Surgical at 10.2%, and Neuroscience at 9.3%. This diversification underscores the company's resilience and market position.
The quarterly results were bolstered by an extra reporting week, which contributed approximately $570 million, or 5.8% of sales. Management emphasized that this calendar benefit is not expected to recur, and investors will be watching whether the company can sustain its growth momentum without this tailwind. The raised guidance suggests confidence in continued strong demand across its product portfolio.
Medtronic's robotics expansion intensifies competition with Intuitive Surgical (NASDAQ: ISRG), the market leader in robotic surgery. Hugo is already used in over 35 countries, and the company projects that total procedures will surpass 50,000 in the current fiscal year. The investment in Cornerstone positions Medtronic to capture a larger share of the minimally invasive surgery market, where robotic adoption remains in the single digits.
Beyond robotics, Medtronic also announced plans to invest up to $80 million in Pi-Cardia, a company specializing in innovative cardiovascular solutions. The deal includes an option to acquire Pi-Cardia for up to $210 million upfront, plus potential earn-outs. This move aligns with Medtronic's strategy to strengthen its cardiovascular portfolio and drive growth through strategic partnerships.
Analysts have responded positively to the news, with 13 out of 19 covering analysts rating the stock as a Buy and six as a Hold, according to Google Finance data. The average price target stands at $96.88, representing a 3.5% premium to the opening price. No analysts currently recommend selling the stock, reflecting optimism about the company's prospects.
However, risks remain. The company's guidance is based on non-GAAP metrics and current foreign exchange rates, and the additional week's contribution will not be repeated. The success of the robotics investments will depend on regulatory approvals and market adoption. Investors will be closely monitoring whether Medtronic can convert its substantial investments into sustainable revenue growth while maintaining profitability.
